Shopping Cart
Remove All
Your shopping cart is currently empty
Toripalimab
Catalog No. T77117 Copy Product Info
Purity: 95%
🥰Excellent
Toripalimab is a recombinant, humanized immunoglobulin G4 (IgG4) monoclonal antibody that specifically targets and blocks the programmed cell death protein 1 (PD-1) immune checkpoint receptor, thereby acting as an immune checkpoint inhibitor used in clinical research for the investigation of advanced or metastatic malignancies, most notably nasopharyngeal carcinoma.
Toripalimab
Copy Product Info🥰Excellent
Catalog No. T77117
Toripalimab is a recombinant, humanized immunoglobulin G4 (IgG4) monoclonal antibody that specifically targets and blocks the programmed cell death protein 1 (PD-1) immune checkpoint receptor, thereby acting as an immune checkpoint inhibitor used in clinical research for the investigation of advanced or metastatic malignancies, most notably nasopharyngeal carcinoma.
Toripalimab
Cas No. 1924598-82-2
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $81 | - | In Stock | |
| 5 mg | $207 | - | In Stock | |
| 10 mg | $330 | - | In Stock | |
| 25 mg | $660 | - | In Stock | |
| 50 mg | $1,060 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:95.2% (SDS-PAGE); 96.8% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Toripalimab is a recombinant, humanized immunoglobulin G4 (IgG4) monoclonal antibody that specifically targets and blocks the programmed cell death protein 1 (PD-1) immune checkpoint receptor, thereby acting as an immune checkpoint inhibitor used in clinical research for the investigation of advanced or metastatic malignancies, most notably nasopharyngeal carcinoma. |
| In vivo | Methods: Toripalimab (0.3-10 mg/kg, intraperitoneal injection, twice a week, 6 times) was used to treat transgenic mice with human PD-1 knockout, and its therapeutic effect on tumors in mice was observed. Results: In the 1, 3, and 10 mg/kg treatment groups, tumor growth inhibition was observed in a dose-dependent manner, demonstrating significant anti-tumor efficacy. [1] |
| Reactivity | Human |
| Verified Activity | Immobilized Human PD-1 Protein (His) (TMPY-00897) at 1 μg/mL (100 μL/well) can bind Toripalimab. The EC50 is 6.96 ng/mL.  |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | PDCD1/PD-1/CD279 |
| Molecular Weight | 147.29 kDa |
| Cas No. | 1924598-82-2 |
| Isotype | Human IgG4 kappa |
| Recommended Isotype Control |
| Storage | -20°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Citations
Calculator
Preview
Related Tags: buy Toripalimab | purchase Toripalimab | Toripalimab cost | order Toripalimab | Toripalimab in vivo | Toripalimab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.